Open the map

Johnson & JohnsonJNJ

Big pharma · NYSE · USA

$256.48
Down 0.8% todayClose

Up 24.9% this year and +0.7% since June 26, behind the life science sector at +10.7%. Johnson & Johnson supplies 2 mapped companies and buys from 2.

This year
+24.9%
1 year
+36.8%
P/E
29.0
P/S
6.2
P/B
7.2

Price vs the life science sector

since Jun 26JNJLife science sector, equal weight
Johnson & Johnson (JNJ) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. JNJ: +0.7% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+5%+10%Jun 26AugSepOct 8JNJ +0.7%Sector +10.7% Johnson & Johnson (JNJ) vs the Life science sector indexDaily closes from Jun 26, 2026 to Oct 8, 2026, each line rebased to its own first value. JNJ: +0.7% from Jun 26, 2026 to Oct 8, 2026. Life science sector index: +10.7% from Jun 26, 2026 to Oct 8, 2026.0%+5%+10%Jun 26AugSepOct 8JNJ+0.7%Sector+10.7%

Supply chain

2 suppliers · 2 customers
SUPPLIERS →→ CUSTOMERSThermo Fisher Scientific (TMO)TMOThermo Fisher Scien…−1.5%West Pharmaceutical Services (WST)WSTWest Pharmaceutical…−0.9%McKesson (MCK)MCKMcKesson+2.2%Cencora (COR)CORCencora+1.3%JNJJohnson & Johns… Open the full chain →

About Johnson & Johnson

Two businesses under one name: Innovative Medicine, which covers immunology and oncology drugs, and MedTech, which makes medical devices and surgical equipment.

Theme exposure

Big pharmaMedtech exposureOncologyMedtech

Products

  • Medicine (immunology/oncology)
  • Medical devices
  • Surgery

Competitors

Risks

  • Litigation (talc)
  • Patent cliff (Stelara)

Same segment: Big pharma

Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas. Segment 2 of 8 in the Medicine, pharma & life science value chain.

Compare JNJ

Side by side with the largest companies in the same segment.

See where Johnson & Johnson sits in the full Medicine, pharma & life science map: every segment from upstream suppliers to end markets, with daily metrics.

Open the Life science value chain →